Periscope Capital’s TriSalus Life Sciences TLSI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-223,656
Closed -$2.22M 944
2022
Q3
$2.22M Buy
223,656
+84,035
+60% +$831K 0.06% 477
2022
Q2
$1.38M Buy
139,621
+39,621
+40% +$389K 0.04% 579
2022
Q1
$980K Sell
100,000
-6,371
-6% -$62.9K 0.03% 621
2021
Q4
$1.05M Sell
106,371
-629
-0.6% -$6.25K 0.03% 574
2021
Q3
$1.06M Buy
+107,000
New +$1.05M 0.03% 552

Other funds holding TLSI

Periscope Capital's TLSI Position: Q4 2022 in Review

Periscope Capital sold out of TriSalus Life Sciences (TLSI) in Q4 2022, closing a stake of 223,656 shares — an estimated $2.22M sold.

Periscope Capital first reported a position in TLSI in Q3 2021 and held it in 5 quarters. The position peaked at $2.22M in Q3 2022. 9 funds tracked by Wall St. Rank hold TLSI as of Q4 2022.

  • Periscope Capital reported no remaining TriSalus Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Periscope Capital sold 223,656 TriSalus Life Sciences shares in Q4 2022, an estimated $2.22M.
  • Periscope Capital first reported a position in TriSalus Life Sciences in Q3 2021 and held it in 5 quarters.
  • Periscope Capital's TriSalus Life Sciences position peaked at $2.22M in Q3 2022.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2022.

Based on Periscope Capital's 13F filing for Q4 2022, filed 13 Feb 2023.